AI-assisted contouring for breast cancer radiation treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

LOCATOR is a multicentre phase II non-inferiority randomised controlled trial that compares AI-assisted contouring using in-house LOCATOR software to fully manual contouring by radiation oncologists for breast cancer patients. The study aims to determine if AI-assisted contouring is of comparable quality and whether it saves time for oncologists. Patients will be randomly assigned to receive either AI-assisted or manual contouring, with the primary endpoint focusing on the quality of the contours as assessed by the MD Anderson Contouring Grade Scale. Secondary endpoints include geometric accuracy, dosimetric differences, and a cost-benefit analysis of the AI contouring tool.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years and older who are planned for primary breast malignancy
* ECOG performance 0-2
* Ability to understand and willingness to sign a written informed consent document
* The target volume must be able to be objectively reviewed by current published national or international clinical guidelines

Exclusion Criteria:

* Patients under 18 years of age
* Patients unable to understand consent documents

Where it's running

• Western Cancer Centre Dubbo
  Dubbo, New South Wales, Australia Recruiting
• Central West Cancer Centre
  Orange, New South Wales, Australia Recruiting
• Department of Radiation Oncology, Royal North Shore Hospital
  St Leonards, New South Wales, Australia Recruiting

Study contacts

• Study coordinator: Joseph Chan, BSc MBBS PhD FRANZCR
• Email: joseph.chan@health.nsw.gov.au
• Phone: 94631300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Seeing what cancer patients eat during radiation treatment using a mobile food diary

  This study tests whether patients undergoing radiation therapy can consistently use a mobile food diary app to log their daily meals.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07682714

• CAIX PET/CT–guided radiation for clear cell kidney cancer

  This trial will try using CAIX-targeted PET/CT scans plus FDG PET/CT to guide focused stereotactic radiation alongside standard targeted therapy and anti‑PD‑1 immunotherapy for adults with recurrent or metastatic clear cell kidney cancer.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07540260

• Radiation therapy options compared for newly diagnosed gynecologic cancers

  This study tests whether proton therapy works as well as conventional photon therapy for endometrial and cervical cancers.

  Recruiting at 5 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 4 other locations · NCT07415681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.